Cargando…

Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss

The amplification of YWHAZ was commonly seen in bladder cancer. We explore the biological significance of YWHAZ amplification on bladder cancer, and the correlation with important other molecular events. The Cancer Genome Atlas (TCGA) database was exploited to study the impact of YWHAZ amplification...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shenghua, Wu, Yishuo, Yang, Tian, Feng, Chenchen, Jiang, Haowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085186/ https://www.ncbi.nlm.nih.gov/pubmed/27167196 http://dx.doi.org/10.18632/oncotarget.9158

Ejemplares similares

Knockdown of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) enhances tumorigenesis both in vivo and in vitro in bladder cancer
por: Liu, Shenghua, et al.
Publicado: (2018)

YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo‐/radio‐resistance by suppressing caspase‐mediated apoptosis
por: Yu, Chia‐Cheng, et al.
Publicado: (2019)

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
por: Soto, José Luis, et al.
Publicado: (2005)

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer
por: Li, Yang, et al.
Publicado: (2010)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas
por: Pessôa, Igor Andrade, et al.
Publicado: (2019)

NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
por: Galipeau, Patricia C, et al.
Publicado: (2007)

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis
por: Zheng, Chang, et al.
Publicado: (2020)

miR-106b regulates the proliferation and differentiation of neural stem/progenitor cells through Tp53inp1-Tp53-Cdkn1a axis
por: Xia, Xiaohuan, et al.
Publicado: (2019)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification
por: Lin, Xiaoyi, et al.
Publicado: (2022)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Convergent TP53 loss and evolvability in cancer
por: Mansur, Marcela Braga, et al.
Publicado: (2023)

MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation
por: Kunc, Michal, et al.
Publicado: (2019)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

The Evaluation of the Risk Factors for Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence after Transurethral Resection (TURBt) in Chinese Population
por: Liu, Shenghua, et al.
Publicado: (2015)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer
por: Pallocca, Matteo, et al.
Publicado: (2018)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2016)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
por: DeLeon, Thomas T., et al.
Publicado: (2020)

TP53 Mutations and CDKN2A Mutations/Deletions are Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papillomas
por: Brown, Noah A., et al.
Publicado: (2020)

Expression of ywhaz and gene regulation network in hepatocellular carcinoma
por: Lin, Yi, et al.
Publicado: (2020)

The role of YWHAZ in cancer: A maze of opportunities and challenges
por: Gan, Yun, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

A TP53-based immune prognostic model for muscle-invasive bladder cancer
por: Li, Hongyan, et al.
Publicado: (2020)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
por: Khan, Safir Ullah, et al.
Publicado: (2023)

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study
por: Tao, Yuting, et al.
Publicado: (2022)

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes
por: Wang, Peiyuan, et al.
Publicado: (2021)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

TP53 loss creates therapeutic vulnerability in colorectal cancer
por: Liu, Yunhua, et al.
Publicado: (2015)

Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation‐dependent probe amplification
por: Bazrafshani, Mohammad Reza R., et al.
Publicado: (2015)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Huaier Inhibits Proliferation, Migration, and Invasion of Cutaneous Squamous Cell Carcinoma Cells by Inhibiting the Methylation Levels of CDKN2A and TP53
por: Wang, Liang, et al.
Publicado: (2021)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6eg5bcfgnof1d5pl8c30qn67bm